secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001193125-25-140873
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince raises $11.5M in private placement of stock and warrants; management participates
--------------------------------------------------------------------------------

- Sold 6,671,928 shares, 2M pre-funded warrants, and 8,671,928 common warrants for $11.5M gross proceeds.
- Common warrants exercisable at $1.20/share for 5 years; pre-funded warrants exercisable at $0.001/share.
- Management investors: CEO Dirk Thye ($200k), COO Brendan Hannah ($50k), President Charles Ryan ($10k).
- Company to file resale registration statement within 120 days under Registration Rights Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312525140873/0001193125-25-140873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312525140873/d31831d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-140873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer